The global blood group typing market size was valued at USD 2.31 billion in 2025 and is projected to reach USD 5.59 billion by 2033, growing at a CAGR of 11.99% from 2026 to 2033. The industry is witnessing substantial growth due to the increasing demand for accurate blood compatibility testing and the rising prevalence of chronic diseases requiring blood transfusion procedures. Blood group typing plays a critical role in ensuring safe transfusions, organ transplantation, prenatal testing, and disease diagnosis. Healthcare providers are increasingly adopting advanced blood typing technologies to improve patient safety, reduce transfusion related complications, and enhance laboratory efficiency. The growing global burden of chronic diseases such as anemia, cancer, hemophilia, sickle cell disease, and other blood disorders is significantly contributing to the increasing need for blood typing and compatibility testing procedures worldwide.

Market growth is driven by the rising burden of chronic diseases such as anemia, cancer, and blood disorders, which increases the need for frequent transfusions. Patients undergoing chemotherapy, surgical procedures, trauma treatment, and long term disease management often require repeated blood transfusions, increasing the demand for reliable blood typing systems and laboratory testing solutions. In addition, the growing number of road accidents, emergency care procedures, and complex surgeries is further supporting the need for accurate blood compatibility testing across healthcare facilities. Governments and healthcare organizations are also focusing on strengthening blood safety infrastructure and improving transfusion services, which is contributing to the adoption of advanced blood group typing technologies globally.

Download a free sample copy of the Blood Group Typing market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

• North America blood group typing market held the largest share of 44.85% of the global market in 2025. The region maintains a strong position due to advanced healthcare infrastructure, widespread adoption of automated diagnostic technologies, and the presence of established blood banking and transfusion systems. Increasing healthcare expenditure, strong regulatory standards, and rising awareness regarding blood safety are further supporting industry growth across North America. In addition, the growing prevalence of chronic diseases and increasing demand for advanced diagnostic testing solutions continue to contribute to the expansion of blood group typing technologies within the region.
• The blood group typing industry in Asia Pacific is expected to grow significantly over the forecast period. Rapid improvements in healthcare infrastructure, increasing investments in diagnostic laboratories, and rising awareness regarding blood donation and transfusion safety are supporting industry growth across the region. Countries such as China, India, Japan, and South Korea are witnessing increasing demand for advanced blood typing technologies due to growing patient populations, rising surgical procedures, and expanding healthcare access. Government initiatives focused on strengthening blood banking infrastructure and improving healthcare services are also expected to accelerate the adoption of blood group typing solutions throughout Asia Pacific.
• By product, the reagents & consumables segment held the highest market share of 71.49% in 2025. The dominance of this segment is primarily attributed to the recurring demand for blood typing reagents, assay kits, antisera, test cards, and laboratory consumables used in routine diagnostic procedures. Hospitals, blood banks, and diagnostic laboratories require continuous supplies of consumables for blood compatibility testing, antibody screening, and cross matching procedures. The increasing volume of blood transfusions and diagnostic testing activities is expected to further strengthen the demand for reagents and consumables worldwide.
• By techniques, the PCR-based and microarray-based segment held the highest market share of 52.04% in 2025. These advanced molecular diagnostic techniques offer high sensitivity, improved accuracy, and rapid detection capabilities for blood group antigen identification. PCR based and microarray technologies are increasingly utilized for complex blood typing applications, prenatal diagnostics, rare blood group identification, and large scale screening programs. The growing adoption of molecular diagnostics and precision medicine approaches is expected to continue supporting the expansion of these advanced testing techniques.
• By test type, the antibody screening segment held the highest market share of 38.91% in 2025. Antibody screening plays a critical role in identifying unexpected antibodies that may cause transfusion reactions or complications during pregnancy and organ transplantation. Healthcare providers are increasingly prioritizing comprehensive antibody screening procedures to ensure transfusion safety and improve patient outcomes. The increasing number of blood transfusion procedures and rising awareness regarding immunohematology testing are contributing significantly to the growth of this segment.
• The increasing focus on personalized medicine, advanced diagnostics, and precision healthcare is expected to create additional opportunities for blood group typing technologies in the future. Healthcare institutions are investing in advanced laboratory automation systems and integrated diagnostic platforms capable of improving testing efficiency and supporting large scale blood management operations. The growing adoption of digital healthcare technologies and connected laboratory systems is also expected to enhance workflow management and data accuracy within blood typing laboratories.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

The blood group typing market is moderately fragmented, with the presence of both multinational corporations and regional players competing across product segments. Despite fragmentation, competition remains intense due to ongoing technological advancements and increasing demand for accurate transfusion diagnostics. Key companies operating in this market include Grifols S.A., Merck KGaA, Bio-Rad Laboratories, Inc., Immucor, Inc., Novacyt Group, Danaher Corporation, Agena Bioscience, Inc., Ortho Clinical Diagnostics, and Quotient, Ltd. These players focus on product innovation, automation, and strategic collaborations to strengthen their market position and expand global reach.

Key Blood Group Typing Companies:

• Grifols S.A.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Immucor, Inc
• Novacyt Group
• Danaher Corporation
• Agena Bioscience, Inc.
• Ortho Clinical Diagnostics
• Quotient, Ltd.

Explore Grand View Horizon to see global and regional level statistics related to the Blood Group Typing Market

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments.
• Extended forecast timelines for long-term planning.
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments.
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making
• And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering